Literature DB >> 32753471

A LHFPL3-AS1/miR-580-3p/STAT3 Feedback Loop Promotes the Malignancy in Melanoma via Activation of JAK2/STAT3 Signaling.

Qian Peng1, Linbo Liu1, Hui Pei2, Jianwen Zhang1, Minjing Chen1, Xiaomei Zhai3.   

Abstract

Melanoma is one of the severe skin cancers, accounting for three fourths of all deaths caused by skin cancers and gathering attention from researchers. Previous studies have elucidated that long noncoding RNAs (lncRNA) engage actively in tissue physiology and disease development, especially in tumorigenesis. LncRNA LHFPL3 antisense RNA 1 (LHFPL3-AS1) has rarely been mentioned in researches regarding cancers; therefore, the underlying role and function of LHFPL3-AS1 in melanoma arouse our interest. Data from our work suggested that LHFPL3-AS1 expression was markedly elevated in melanoma tissues and cells. Of note, patients with melanoma with high level of LHFPL3-AS1 were burdened with unfavorable prognosis. Functionally, it has been revealed that LHFPL3-AS1 exerted pro-growth, pro-invasion, and pro-EMT functions in melanoma. Mechanistically, it was figured out that LHFPL3-AS1 could be transcriptionally activated by STAT3. In turn, LHFPL3-AS1 served as a sponge of miR-580-3p to augment STAT3 expression, resulting in activated JAK2/STAT3 signaling pathway in melanoma. IMPLICATIONS: Our study revealed a novel positive feedback loop LHFPL3-AS1/miR-580-3p/STAT3 in melanoma, which might contribute to finding potential therapeutic targets for melanoma. ©2020 American Association for Cancer Research.

Entities:  

Year:  2020        PMID: 32753471     DOI: 10.1158/1541-7786.MCR-19-1046

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  8 in total

1.  Transcriptomic Profiling of Gene Expression Associated with Granulosa Cell Tumor Development in a Mouse Model.

Authors:  Nan Ni; Xin Fang; Destiny A Mullens; James J Cai; Ivan Ivanov; Laurent Bartholin; Qinglei Li
Journal:  Cancers (Basel)       Date:  2022-04-27       Impact factor: 6.575

2.  Down-regulated long non-coding RNA LHFPL3 antisense RNA 1 inhibits the radiotherapy resistance of nasopharyngeal carcinoma via modulating microRNA-143-5p/homeobox A6 axis.

Authors:  Weifeng Wang; Zhuo Zhang; Yundong Li; Anqi Gu; Yingyin Wang; Yizheng Cai; Yajie Yu; Xiaocong Deng
Journal:  Bioengineered       Date:  2022-03       Impact factor: 6.832

3.  LncRNA LHFPL3-AS1 Promotes Oral Squamous Cell Carcinoma Growth and Cisplatin Resistance Through Targeting miR-362-5p/CHSY1 Pathway.

Authors:  Jiandong Li; Xiaohu Xu; Dandan Zhang; Han Lv; Xin Lei
Journal:  Onco Targets Ther       Date:  2021-03-31       Impact factor: 4.147

4.  Long Non-Coding RNA CD27-AS1-208 Facilitates Melanoma Progression by Activating STAT3 Pathway.

Authors:  Jingjing Ma; Qiong Shi; Sen Guo; Peng Xu; Xiuli Yi; Yuqi Yang; Weigang Zhang; Yu Liu; Lin Liu; Qiao Yue; Tao Zhao; Tianwen Gao; Weinan Guo; Chunying Li
Journal:  Front Oncol       Date:  2022-01-13       Impact factor: 6.244

Review 5.  Regulation of LncRNAs in Melanoma and Their Functional Roles in the Metastatic Process.

Authors:  Marine Melixetian; Pier Giuseppe Pelicci; Luisa Lanfrancone
Journal:  Cells       Date:  2022-02-07       Impact factor: 6.600

6.  Long Noncoding RNA RMRP Contributes to Paclitaxel Sensitivity of Ovarian Cancer by Regulating miR-580-3p/MICU1 Signaling.

Authors:  Lingling Li; Saitian Zeng; Liang Guo; Ping Huang; Jie Xi; Jing Feng; Qian Li; Yanying Li; Xiyun Xiao; Ruixue Yan; Jiyan Zhang
Journal:  J Oncol       Date:  2022-01-29       Impact factor: 4.375

7.  Integrated Analysis of Genes Associated With Immune Microenvironment and Distant Metastasis in Uveal Melanoma.

Authors:  Wenchuan Zhou; Jing Li
Journal:  Front Cell Dev Biol       Date:  2022-03-30

8.  CircRAB3IP upregulates twist family BHLH transcription factor (TWIST1) to promote osteosarcoma progression by sponging miR-580-3p.

Authors:  Guojun Tang; Linghua Liu; Zhihong Xiao; Shuo Wen; Liangyuan Chen; Peng Yang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.